SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Shorvon SD, van Rijckevorsel K. A new antiepileptic drug. J Neurol Neurosurg Psychiatry 2002;72: 426428.
  • 2
    French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001;47: 7790.
  • 3
    Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46: 259270.
  • 4
    Cereghino JJ, Biton V, Abou-Khalil B, et al. and the United States Levetiracetam Study Group. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55: 236242.
  • 5
    Shorvon SD, Löwenthal A, Janz D, et al. and the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41: 11791186.
  • 6
    Ben-Menachem E, Falter U, and the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41: 12761283.
  • 7
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: ethnic factors in the acceptability of foreign clinical data E5. Recommended for Adoption at Step 4 of the ICH Process on 5 February 1998 by the ICH Steering Committee (including Post Step 4 corrections agreed by the Steering Committee on 11 March 1998). Accessible at http://www.ich.org.
  • 8
    Announcement of Bridging Study, Department of Health, Taiwan. Accessible at http://www.cde.org.tw/BS.web.cht/main.htm
  • 9
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6. Recommended for Adoption at Step 4 of the ICH Process on 1 May 1996 by the ICH Steering Committee (including Post Step 4 corrections agreed by the Steering Committee on 10 June 1996). Accessible at http://www.ich.org.
  • 10
    Altman DG, Schulz KF, Moher D, et al. for the CONSORT Group. The Revised CONSORT Statement for Reporting Randomized Trials: explanation and elaboration. Ann Intern Med 2001;134: 663694.
  • 11
    French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005;46: 324326.
  • 12
    French J, di Nicola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005 (in press).
  • 13
    Somerville R. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002;59: 7983.
  • 14
    Ben-Menachem E, Edrich P, van Vleymen B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 2003;53: 5764.
  • 15
    Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27: 250254.
  • 16
    Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348: 529537.
  • 17
    Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52: 349355.
  • 18
    Spear BB. Pharmacogenetics and antiepileptic drugs. Epilepsia 2001;42(suppl 5):3134.
  • 19
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38: 233234.
  • 20
    Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 2001;47: 1725.
  • 21
    Eng CO, Arrigo C, van Rijckevorsel K, et al. Meta-analysis and indirect comparison of levetiracetam with second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28: 7278.